nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—Tamibarotene—RARB—head and neck cancer	0.051	1	CrCbGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—RARB—head and neck cancer	0.019	0.0425	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—RARB—head and neck cancer	0.0179	0.0399	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—RARB—head and neck cancer	0.017	0.0379	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—RARB—head and neck cancer	0.016	0.0356	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—RARB—head and neck cancer	0.014	0.0313	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—CEBPA—head and neck cancer	0.0138	0.0309	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—CEBPA—head and neck cancer	0.0137	0.0306	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—RARB—head and neck cancer	0.0132	0.0295	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—CEBPA—head and neck cancer	0.013	0.029	CbGpPWpGaD
Bexarotene—RXRG—Vitamin A and Carotenoid Metabolism—RARB—head and neck cancer	0.0127	0.0284	CbGpPWpGaD
Bexarotene—RXRB—Vitamin A and Carotenoid Metabolism—RARB—head and neck cancer	0.012	0.0267	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—RARB—head and neck cancer	0.0111	0.0248	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—RARB—head and neck cancer	0.0104	0.0233	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—RARB—head and neck cancer	0.00933	0.0208	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—RARB—head and neck cancer	0.00832	0.0186	CbGpPWpGaD
Bexarotene—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—YAP1—head and neck cancer	0.00777	0.0173	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—RARB—head and neck cancer	0.00688	0.0154	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—CEBPA—head and neck cancer	0.00678	0.0151	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—CEBPA—head and neck cancer	0.00675	0.0151	CbGpPWpGaD
Bexarotene—RXRA—Vitamin A and Carotenoid Metabolism—RARB—head and neck cancer	0.00624	0.0139	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—BCL2—head and neck cancer	0.0061	0.0136	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—BCL2—head and neck cancer	0.00573	0.0128	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—RARB—head and neck cancer	0.00544	0.0121	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—STAT6—head and neck cancer	0.0054	0.012	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—CEBPA—head and neck cancer	0.00503	0.0112	CbGpPWpGaD
Bexarotene—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00458	0.0102	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—CDH1—head and neck cancer	0.00453	0.0101	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—CDH1—head and neck cancer	0.00426	0.0095	CbGpPWpGaD
Bexarotene—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00416	0.00929	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—MAPK3—head and neck cancer	0.00385	0.00859	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—MAPK1—head and neck cancer	0.00366	0.00817	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—MAPK3—head and neck cancer	0.00362	0.00808	CbGpPWpGaD
Bexarotene—Hepatic failure—Hydroxyurea—head and neck cancer	0.00358	0.00716	CcSEcCtD
Bexarotene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00354	0.0079	CbGpPWpGaD
Bexarotene—Cellulitis—Fluorouracil—head and neck cancer	0.00351	0.00701	CcSEcCtD
Bexarotene—Herpes simplex—Fluorouracil—head and neck cancer	0.00347	0.00692	CcSEcCtD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—MAPK1—head and neck cancer	0.00344	0.00768	CbGpPWpGaD
Bexarotene—Redness—Docetaxel—head and neck cancer	0.00341	0.00682	CcSEcCtD
Bexarotene—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00337	0.00673	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—CEBPA—head and neck cancer	0.00331	0.00738	CbGpPWpGaD
Bexarotene—Dermatitis contact—Fluorouracil—head and neck cancer	0.00316	0.0063	CcSEcCtD
Bexarotene—Face oedema—Hydroxyurea—head and neck cancer	0.00311	0.00621	CcSEcCtD
Bexarotene—Neuritis—Docetaxel—head and neck cancer	0.00309	0.00617	CcSEcCtD
Bexarotene—Scotoma—Docetaxel—head and neck cancer	0.00304	0.00606	CcSEcCtD
Bexarotene—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00302	0.00603	CcSEcCtD
Bexarotene—Pleural effusion—Docetaxel—head and neck cancer	0.00301	0.00601	CcSEcCtD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—BCL2—head and neck cancer	0.00299	0.00667	CbGpPWpGaD
Bexarotene—Angina pectoris—Vinblastine—head and neck cancer	0.00297	0.00594	CcSEcCtD
Bexarotene—Rash maculo-papular—Fluorouracil—head and neck cancer	0.0029	0.0058	CcSEcCtD
Bexarotene—Pancytopenia—Vinblastine—head and neck cancer	0.0029	0.00579	CcSEcCtD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00281	0.00627	CbGpPWpGaD
Bexarotene—Sepsis—Fluorouracil—head and neck cancer	0.00277	0.00554	CcSEcCtD
Bexarotene—RXRG—Vitamin A and Carotenoid Metabolism—MAPK1—head and neck cancer	0.00275	0.00613	CbGpPWpGaD
Bexarotene—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.00275	0.00613	CbGpPWpGaD
Bexarotene—Pancreatitis—Hydroxyurea—head and neck cancer	0.00273	0.00545	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—YAP1—head and neck cancer	0.00268	0.00597	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00267	0.00533	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—head and neck cancer	0.00265	0.00591	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—STAT6—head and neck cancer	0.00265	0.0059	CbGpPWpGaD
Bexarotene—Pancytopenia—Hydroxyurea—head and neck cancer	0.00264	0.00528	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—head and neck cancer	0.00262	0.00584	CbGpPWpGaD
Bexarotene—Neutropenia—Hydroxyurea—head and neck cancer	0.0026	0.0052	CcSEcCtD
Bexarotene—Dysuria—Hydroxyurea—head and neck cancer	0.0026	0.0052	CcSEcCtD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—AKT1—head and neck cancer	0.0026	0.00579	CbGpPWpGaD
Bexarotene—RXRB—Vitamin A and Carotenoid Metabolism—MAPK1—head and neck cancer	0.00258	0.00576	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—CCND1—head and neck cancer	0.00257	0.00572	CbGpPWpGaD
Bexarotene—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00254	0.00506	CcSEcCtD
Bexarotene—Weight increased—Hydroxyurea—head and neck cancer	0.00253	0.00506	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—head and neck cancer	0.00249	0.00555	CbGpPWpGaD
Bexarotene—Haemoglobin—Vinblastine—head and neck cancer	0.00246	0.0049	CcSEcCtD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00245	0.00546	CbGpPWpGaD
Bexarotene—Haemorrhage—Vinblastine—head and neck cancer	0.00244	0.00488	CcSEcCtD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—head and neck cancer	0.00244	0.00545	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00243	0.00486	CcSEcCtD
Bexarotene—Hypoaesthesia—Vinblastine—head and neck cancer	0.00243	0.00486	CcSEcCtD
Bexarotene—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00243	0.00484	CcSEcCtD
Bexarotene—Pharyngitis—Vinblastine—head and neck cancer	0.00243	0.00484	CcSEcCtD
Bexarotene—Stomatitis—Hydroxyurea—head and neck cancer	0.00242	0.00483	CcSEcCtD
Bexarotene—Bone pain—Docetaxel—head and neck cancer	0.00241	0.00481	CcSEcCtD
Bexarotene—Lethargy—Fluorouracil—head and neck cancer	0.00237	0.00472	CcSEcCtD
Bexarotene—Osteoarthritis—Fluorouracil—head and neck cancer	0.00232	0.00463	CcSEcCtD
Bexarotene—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00231	0.0046	CcSEcCtD
Bexarotene—Hepatocellular injury—Docetaxel—head and neck cancer	0.00231	0.0046	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—PIK3CA—head and neck cancer	0.0023	0.00513	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—NAT2—head and neck cancer	0.00225	0.00502	CbGpPWpGaD
Bexarotene—Haemoglobin—Hydroxyurea—head and neck cancer	0.00224	0.00447	CcSEcCtD
Bexarotene—Haemorrhage—Hydroxyurea—head and neck cancer	0.00223	0.00445	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—CDH1—head and neck cancer	0.00222	0.00495	CbGpPWpGaD
Bexarotene—Colitis—Docetaxel—head and neck cancer	0.00221	0.00442	CcSEcCtD
Bexarotene—Candida infection—Docetaxel—head and neck cancer	0.0022	0.0044	CcSEcCtD
Bexarotene—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.0022	0.0049	CbGpPWpGaD
Bexarotene—Fluid retention—Docetaxel—head and neck cancer	0.00219	0.00437	CcSEcCtD
Bexarotene—RXRA—NRF2 pathway—TGFA—head and neck cancer	0.00218	0.00486	CbGpPWpGaD
Bexarotene—Ataxia—Fluorouracil—head and neck cancer	0.00218	0.00435	CcSEcCtD
Bexarotene—Neuropathy—Docetaxel—head and neck cancer	0.00216	0.00432	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—PIK3CA—head and neck cancer	0.00216	0.00482	CbGpPWpGaD
Bexarotene—Alopecia—Vinblastine—head and neck cancer	0.00216	0.00431	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—head and neck cancer	0.00213	0.00474	CbGpPWpGaD
Bexarotene—Dry skin—Fluorouracil—head and neck cancer	0.00213	0.00424	CcSEcCtD
Bexarotene—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00211	0.00472	CbGpPWpGaD
Bexarotene—Neoplasm—Docetaxel—head and neck cancer	0.00208	0.00416	CcSEcCtD
Bexarotene—Pulmonary oedema—Docetaxel—head and neck cancer	0.00205	0.0041	CcSEcCtD
Bexarotene—Muscular weakness—Fluorouracil—head and neck cancer	0.00204	0.00408	CcSEcCtD
Bexarotene—Angiopathy—Hydroxyurea—head and neck cancer	0.00202	0.00404	CcSEcCtD
Bexarotene—Dysphagia—Fluorouracil—head and neck cancer	0.002	0.004	CcSEcCtD
Bexarotene—Sepsis—Docetaxel—head and neck cancer	0.002	0.00399	CcSEcCtD
Bexarotene—Chills—Hydroxyurea—head and neck cancer	0.002	0.00399	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—head and neck cancer	0.002	0.00446	CbGpPWpGaD
Bexarotene—Eosinophilia—Fluorouracil—head and neck cancer	0.00198	0.00396	CcSEcCtD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00198	0.00442	CbGpPWpGaD
Bexarotene—Ill-defined disorder—Vinblastine—head and neck cancer	0.00197	0.00394	CcSEcCtD
Bexarotene—Alopecia—Hydroxyurea—head and neck cancer	0.00197	0.00393	CcSEcCtD
Bexarotene—Anaemia—Vinblastine—head and neck cancer	0.00197	0.00393	CcSEcCtD
Bexarotene—Angina pectoris—Fluorouracil—head and neck cancer	0.00195	0.0039	CcSEcCtD
Bexarotene—Erythema—Hydroxyurea—head and neck cancer	0.00194	0.00387	CcSEcCtD
Bexarotene—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00192	0.00384	CcSEcCtD
Bexarotene—Malaise—Vinblastine—head and neck cancer	0.00192	0.00383	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—RARB—head and neck cancer	0.00192	0.00428	CbGpPWpGaD
Bexarotene—Vertigo—Vinblastine—head and neck cancer	0.00191	0.00382	CcSEcCtD
Bexarotene—Leukopenia—Vinblastine—head and neck cancer	0.0019	0.0038	CcSEcCtD
Bexarotene—Pancytopenia—Fluorouracil—head and neck cancer	0.0019	0.0038	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.00189	0.00422	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—MAPK3—head and neck cancer	0.00189	0.00421	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—AKT1—head and neck cancer	0.00188	0.00419	CbGpPWpGaD
Bexarotene—Deafness—Docetaxel—head and neck cancer	0.00187	0.00374	CcSEcCtD
Bexarotene—Hepatic failure—Docetaxel—head and neck cancer	0.00186	0.00372	CcSEcCtD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00185	0.00413	CbGpPWpGaD
Bexarotene—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00185	0.00368	CcSEcCtD
Bexarotene—Hypertension—Vinblastine—head and neck cancer	0.00184	0.00367	CcSEcCtD
Bexarotene—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00183	0.00365	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	0.0018	0.00403	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—RARB—head and neck cancer	0.0018	0.00402	CbGpPWpGaD
Bexarotene—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0018	0.00359	CcSEcCtD
Bexarotene—Pneumonia—Fluorouracil—head and neck cancer	0.0018	0.00359	CcSEcCtD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—MAPK1—head and neck cancer	0.0018	0.004	CbGpPWpGaD
Bexarotene—Anaemia—Hydroxyurea—head and neck cancer	0.00179	0.00358	CcSEcCtD
Bexarotene—Discomfort—Vinblastine—head and neck cancer	0.00179	0.00357	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—head and neck cancer	0.00177	0.00394	CbGpPWpGaD
Bexarotene—Renal impairment—Docetaxel—head and neck cancer	0.00176	0.00351	CcSEcCtD
Bexarotene—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00175	0.0035	CcSEcCtD
Bexarotene—Dermatitis bullous—Docetaxel—head and neck cancer	0.00175	0.0035	CcSEcCtD
Bexarotene—Malaise—Hydroxyurea—head and neck cancer	0.00175	0.00349	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—YAP1—head and neck cancer	0.00174	0.00389	CbGpPWpGaD
Bexarotene—Stomatitis—Fluorouracil—head and neck cancer	0.00174	0.00348	CcSEcCtD
Bexarotene—Conjunctivitis—Fluorouracil—head and neck cancer	0.00174	0.00347	CcSEcCtD
Bexarotene—Urinary tract infection—Fluorouracil—head and neck cancer	0.00174	0.00347	CcSEcCtD
Bexarotene—Leukopenia—Hydroxyurea—head and neck cancer	0.00174	0.00347	CcSEcCtD
Bexarotene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00173	0.00387	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.00172	0.00384	CbGpPWpGaD
Bexarotene—Lethargy—Docetaxel—head and neck cancer	0.00171	0.00341	CcSEcCtD
Bexarotene—Thrombocytopenia—Vinblastine—head and neck cancer	0.0017	0.00339	CcSEcCtD
Bexarotene—Epistaxis—Fluorouracil—head and neck cancer	0.00169	0.00337	CcSEcCtD
Bexarotene—Hyponatraemia—Docetaxel—head and neck cancer	0.00168	0.00336	CcSEcCtD
Bexarotene—Sinusitis—Fluorouracil—head and neck cancer	0.00168	0.00335	CcSEcCtD
Bexarotene—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.00166	0.00371	CbGpPWpGaD
Bexarotene—Anorexia—Vinblastine—head and neck cancer	0.00165	0.0033	CcSEcCtD
Bexarotene—Migraine—Docetaxel—head and neck cancer	0.00165	0.00329	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—YAP1—head and neck cancer	0.00164	0.00366	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00164	0.00328	CcSEcCtD
Bexarotene—Discomfort—Hydroxyurea—head and neck cancer	0.00163	0.00326	CcSEcCtD
Bexarotene—Haemoglobin—Fluorouracil—head and neck cancer	0.00161	0.00322	CcSEcCtD
Bexarotene—Rhinitis—Fluorouracil—head and neck cancer	0.00161	0.00321	CcSEcCtD
Bexarotene—Haemorrhage—Fluorouracil—head and neck cancer	0.0016	0.0032	CcSEcCtD
Bexarotene—Hypoaesthesia—Fluorouracil—head and neck cancer	0.0016	0.00319	CcSEcCtD
Bexarotene—Pharyngitis—Fluorouracil—head and neck cancer	0.00159	0.00318	CcSEcCtD
Bexarotene—Oedema—Hydroxyurea—head and neck cancer	0.00158	0.00316	CcSEcCtD
Bexarotene—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00158	0.00352	CbGpPWpGaD
Bexarotene—Ataxia—Docetaxel—head and neck cancer	0.00157	0.00314	CcSEcCtD
Bexarotene—Infection—Hydroxyurea—head and neck cancer	0.00157	0.00314	CcSEcCtD
Bexarotene—Paraesthesia—Vinblastine—head and neck cancer	0.00156	0.00311	CcSEcCtD
Bexarotene—Dehydration—Docetaxel—head and neck cancer	0.00156	0.00311	CcSEcCtD
Bexarotene—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00155	0.0031	CcSEcCtD
Bexarotene—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00155	0.0031	CcSEcCtD
Bexarotene—Liver function test abnormal—Docetaxel—head and neck cancer	0.00154	0.00309	CcSEcCtD
Bexarotene—Skin disorder—Hydroxyurea—head and neck cancer	0.00154	0.00307	CcSEcCtD
Bexarotene—Dry skin—Docetaxel—head and neck cancer	0.00153	0.00306	CcSEcCtD
Bexarotene—Anorexia—Hydroxyurea—head and neck cancer	0.00151	0.00301	CcSEcCtD
Bexarotene—Decreased appetite—Vinblastine—head and neck cancer	0.00151	0.00301	CcSEcCtD
Bexarotene—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00151	0.00301	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—CYP1A1—head and neck cancer	0.00151	0.00336	CbGpPWpGaD
Bexarotene—Pain—Vinblastine—head and neck cancer	0.00148	0.00296	CcSEcCtD
Bexarotene—Constipation—Vinblastine—head and neck cancer	0.00148	0.00296	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00148	0.00295	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—head and neck cancer	0.00147	0.00329	CbGpPWpGaD
Bexarotene—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00145	0.00323	CbGpPWpGaD
Bexarotene—Dysphagia—Docetaxel—head and neck cancer	0.00145	0.00289	CcSEcCtD
Bexarotene—Arrhythmia—Fluorouracil—head and neck cancer	0.00143	0.00286	CcSEcCtD
Bexarotene—Feeling abnormal—Vinblastine—head and neck cancer	0.00143	0.00286	CcSEcCtD
Bexarotene—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00142	0.00283	CcSEcCtD
Bexarotene—Alopecia—Fluorouracil—head and neck cancer	0.00142	0.00283	CcSEcCtD
Bexarotene—Dyspnoea—Hydroxyurea—head and neck cancer	0.00141	0.00282	CcSEcCtD
Bexarotene—Angina pectoris—Docetaxel—head and neck cancer	0.00141	0.00281	CcSEcCtD
Bexarotene—Somnolence—Hydroxyurea—head and neck cancer	0.00141	0.00281	CcSEcCtD
Bexarotene—Erythema—Fluorouracil—head and neck cancer	0.0014	0.00279	CcSEcCtD
Bexarotene—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00139	0.00311	CbGpPWpGaD
Bexarotene—Dyspepsia—Hydroxyurea—head and neck cancer	0.00139	0.00278	CcSEcCtD
Bexarotene—Decreased appetite—Hydroxyurea—head and neck cancer	0.00138	0.00275	CcSEcCtD
Bexarotene—Pancytopenia—Docetaxel—head and neck cancer	0.00137	0.00274	CcSEcCtD
Bexarotene—Abdominal pain—Vinblastine—head and neck cancer	0.00137	0.00274	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00137	0.00273	CcSEcCtD
Bexarotene—Fatigue—Hydroxyurea—head and neck cancer	0.00136	0.00273	CcSEcCtD
Bexarotene—Constipation—Hydroxyurea—head and neck cancer	0.00135	0.0027	CcSEcCtD
Bexarotene—Pain—Hydroxyurea—head and neck cancer	0.00135	0.0027	CcSEcCtD
Bexarotene—Neutropenia—Docetaxel—head and neck cancer	0.00135	0.0027	CcSEcCtD
Bexarotene—RXRA—Vitamin A and Carotenoid Metabolism—MAPK1—head and neck cancer	0.00135	0.003	CbGpPWpGaD
Bexarotene—Weight increased—Docetaxel—head and neck cancer	0.00132	0.00263	CcSEcCtD
Bexarotene—Weight decreased—Docetaxel—head and neck cancer	0.00131	0.00261	CcSEcCtD
Bexarotene—Feeling abnormal—Hydroxyurea—head and neck cancer	0.0013	0.00261	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—head and neck cancer	0.0013	0.00289	CbGpPWpGaD
Bexarotene—Pneumonia—Docetaxel—head and neck cancer	0.0013	0.00259	CcSEcCtD
Bexarotene—Anaemia—Fluorouracil—head and neck cancer	0.00129	0.00258	CcSEcCtD
Bexarotene—Hypersensitivity—Vinblastine—head and neck cancer	0.00128	0.00255	CcSEcCtD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—AKT1—head and neck cancer	0.00127	0.00284	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—GSTM1—head and neck cancer	0.00127	0.00283	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00126	0.00252	CcSEcCtD
Bexarotene—Jaundice—Docetaxel—head and neck cancer	0.00126	0.00251	CcSEcCtD
Bexarotene—Stomatitis—Docetaxel—head and neck cancer	0.00126	0.00251	CcSEcCtD
Bexarotene—Conjunctivitis—Docetaxel—head and neck cancer	0.00125	0.0025	CcSEcCtD
Bexarotene—Body temperature increased—Hydroxyurea—head and neck cancer	0.00125	0.0025	CcSEcCtD
Bexarotene—Leukopenia—Fluorouracil—head and neck cancer	0.00125	0.0025	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—STAT3—head and neck cancer	0.00125	0.00278	CbGpPWpGaD
Bexarotene—Asthenia—Vinblastine—head and neck cancer	0.00125	0.00249	CcSEcCtD
Bexarotene—Epistaxis—Docetaxel—head and neck cancer	0.00122	0.00243	CcSEcCtD
Bexarotene—Myalgia—Fluorouracil—head and neck cancer	0.00119	0.00237	CcSEcCtD
Bexarotene—Chest pain—Fluorouracil—head and neck cancer	0.00119	0.00237	CcSEcCtD
Bexarotene—Diarrhoea—Vinblastine—head and neck cancer	0.00119	0.00237	CcSEcCtD
Bexarotene—Discomfort—Fluorouracil—head and neck cancer	0.00117	0.00235	CcSEcCtD
Bexarotene—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00117	0.00233	CcSEcCtD
Bexarotene—Haemoglobin—Docetaxel—head and neck cancer	0.00116	0.00232	CcSEcCtD
Bexarotene—Rhinitis—Docetaxel—head and neck cancer	0.00116	0.00232	CcSEcCtD
Bexarotene—Haemorrhage—Docetaxel—head and neck cancer	0.00116	0.00231	CcSEcCtD
Bexarotene—Hypoaesthesia—Docetaxel—head and neck cancer	0.00115	0.0023	CcSEcCtD
Bexarotene—Confusional state—Fluorouracil—head and neck cancer	0.00115	0.00229	CcSEcCtD
Bexarotene—Pharyngitis—Docetaxel—head and neck cancer	0.00115	0.00229	CcSEcCtD
Bexarotene—Dizziness—Vinblastine—head and neck cancer	0.00115	0.00229	CcSEcCtD
Bexarotene—Urinary tract disorder—Docetaxel—head and neck cancer	0.00114	0.00228	CcSEcCtD
Bexarotene—Oedema peripheral—Docetaxel—head and neck cancer	0.00114	0.00228	CcSEcCtD
Bexarotene—Oedema—Fluorouracil—head and neck cancer	0.00114	0.00228	CcSEcCtD
Bexarotene—Connective tissue disorder—Docetaxel—head and neck cancer	0.00114	0.00227	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—CEBPA—head and neck cancer	0.00114	0.00254	CbGpPWpGaD
Bexarotene—Asthenia—Hydroxyurea—head and neck cancer	0.00114	0.00227	CcSEcCtD
Bexarotene—Urethral disorder—Docetaxel—head and neck cancer	0.00113	0.00227	CcSEcCtD
Bexarotene—Infection—Fluorouracil—head and neck cancer	0.00113	0.00226	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—PIK3CA—head and neck cancer	0.00113	0.00251	CbGpPWpGaD
Bexarotene—Nervous system disorder—Fluorouracil—head and neck cancer	0.00112	0.00223	CcSEcCtD
Bexarotene—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00112	0.00223	CcSEcCtD
Bexarotene—Tachycardia—Fluorouracil—head and neck cancer	0.00111	0.00222	CcSEcCtD
Bexarotene—RXRA—Biological oxidations—GSTM1—head and neck cancer	0.00111	0.00248	CbGpPWpGaD
Bexarotene—Vomiting—Vinblastine—head and neck cancer	0.0011	0.0022	CcSEcCtD
Bexarotene—Headache—Vinblastine—head and neck cancer	0.00109	0.00217	CcSEcCtD
Bexarotene—Anorexia—Fluorouracil—head and neck cancer	0.00109	0.00217	CcSEcCtD
Bexarotene—Diarrhoea—Hydroxyurea—head and neck cancer	0.00108	0.00216	CcSEcCtD
Bexarotene—Eye disorder—Docetaxel—head and neck cancer	0.00108	0.00216	CcSEcCtD
Bexarotene—Cardiac disorder—Docetaxel—head and neck cancer	0.00107	0.00215	CcSEcCtD
Bexarotene—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00107	0.00238	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00106	0.00236	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP1A1—head and neck cancer	0.00105	0.00235	CbGpPWpGaD
Bexarotene—Angiopathy—Docetaxel—head and neck cancer	0.00105	0.0021	CcSEcCtD
Bexarotene—Dizziness—Hydroxyurea—head and neck cancer	0.00105	0.00209	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—head and neck cancer	0.00104	0.00232	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00104	0.00232	CbGpPWpGaD
Bexarotene—Chills—Docetaxel—head and neck cancer	0.00104	0.00207	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00104	0.00207	CcSEcCtD
Bexarotene—Arrhythmia—Docetaxel—head and neck cancer	0.00103	0.00207	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.00103	0.00231	CbGpPWpGaD
Bexarotene—Nausea—Vinblastine—head and neck cancer	0.00103	0.00206	CcSEcCtD
Bexarotene—Insomnia—Fluorouracil—head and neck cancer	0.00103	0.00206	CcSEcCtD
Bexarotene—Paraesthesia—Fluorouracil—head and neck cancer	0.00102	0.00204	CcSEcCtD
Bexarotene—Alopecia—Docetaxel—head and neck cancer	0.00102	0.00204	CcSEcCtD
Bexarotene—Dyspnoea—Fluorouracil—head and neck cancer	0.00102	0.00203	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—head and neck cancer	0.00102	0.00227	CbGpPWpGaD
Bexarotene—Somnolence—Fluorouracil—head and neck cancer	0.00101	0.00202	CcSEcCtD
Bexarotene—Malnutrition—Docetaxel—head and neck cancer	0.00101	0.00201	CcSEcCtD
Bexarotene—Erythema—Docetaxel—head and neck cancer	0.00101	0.00201	CcSEcCtD
Bexarotene—Vomiting—Hydroxyurea—head and neck cancer	0.00101	0.00201	CcSEcCtD
Bexarotene—Dyspepsia—Fluorouracil—head and neck cancer	0.001	0.002	CcSEcCtD
Bexarotene—Rash—Hydroxyurea—head and neck cancer	0.000998	0.00199	CcSEcCtD
Bexarotene—Dermatitis—Hydroxyurea—head and neck cancer	0.000997	0.00199	CcSEcCtD
Bexarotene—Headache—Hydroxyurea—head and neck cancer	0.000992	0.00198	CcSEcCtD
Bexarotene—Decreased appetite—Fluorouracil—head and neck cancer	0.000991	0.00198	CcSEcCtD
Bexarotene—Dysgeusia—Docetaxel—head and neck cancer	0.000987	0.00197	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000984	0.00196	CcSEcCtD
Bexarotene—Back pain—Docetaxel—head and neck cancer	0.000975	0.00195	CcSEcCtD
Bexarotene—Pain—Fluorouracil—head and neck cancer	0.000974	0.00195	CcSEcCtD
Bexarotene—Muscle spasms—Docetaxel—head and neck cancer	0.000969	0.00193	CcSEcCtD
Bexarotene—Nausea—Hydroxyurea—head and neck cancer	0.00094	0.00188	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—RARB—head and neck cancer	0.00094	0.0021	CbGpPWpGaD
Bexarotene—Feeling abnormal—Fluorouracil—head and neck cancer	0.000939	0.00188	CcSEcCtD
Bexarotene—Anaemia—Docetaxel—head and neck cancer	0.000931	0.00186	CcSEcCtD
Bexarotene—RXRA—Metabolism—UROD—head and neck cancer	0.000926	0.00207	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—RARB—head and neck cancer	0.000923	0.00206	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—head and neck cancer	0.00092	0.00205	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000913	0.00204	CbGpPWpGaD
Bexarotene—Syncope—Docetaxel—head and neck cancer	0.000904	0.0018	CcSEcCtD
Bexarotene—Leukopenia—Docetaxel—head and neck cancer	0.000902	0.0018	CcSEcCtD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000901	0.00201	CbGpPWpGaD
Bexarotene—Body temperature increased—Fluorouracil—head and neck cancer	0.000901	0.0018	CcSEcCtD
Bexarotene—Palpitations—Docetaxel—head and neck cancer	0.000891	0.00178	CcSEcCtD
Bexarotene—Loss of consciousness—Docetaxel—head and neck cancer	0.000886	0.00177	CcSEcCtD
Bexarotene—Cough—Docetaxel—head and neck cancer	0.000879	0.00176	CcSEcCtD
Bexarotene—Hypertension—Docetaxel—head and neck cancer	0.00087	0.00174	CcSEcCtD
Bexarotene—RXRB—Gene Expression—RARB—head and neck cancer	0.000868	0.00194	CbGpPWpGaD
Bexarotene—Myalgia—Docetaxel—head and neck cancer	0.000858	0.00171	CcSEcCtD
Bexarotene—Arthralgia—Docetaxel—head and neck cancer	0.000858	0.00171	CcSEcCtD
Bexarotene—Chest pain—Docetaxel—head and neck cancer	0.000858	0.00171	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—YAP1—head and neck cancer	0.000855	0.00191	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000852	0.0017	CcSEcCtD
Bexarotene—RXRG—Gene Expression—YAP1—head and neck cancer	0.00084	0.00187	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.00084	0.00187	CbGpPWpGaD
Bexarotene—Hypersensitivity—Fluorouracil—head and neck cancer	0.00084	0.00168	CcSEcCtD
Bexarotene—Dry mouth—Docetaxel—head and neck cancer	0.000839	0.00168	CcSEcCtD
Bexarotene—Confusional state—Docetaxel—head and neck cancer	0.000829	0.00166	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000828	0.00185	CbGpPWpGaD
Bexarotene—Oedema—Docetaxel—head and neck cancer	0.000822	0.00164	CcSEcCtD
Bexarotene—Infection—Docetaxel—head and neck cancer	0.000817	0.00163	CcSEcCtD
Bexarotene—Shock—Docetaxel—head and neck cancer	0.000809	0.00162	CcSEcCtD
Bexarotene—Nervous system disorder—Docetaxel—head and neck cancer	0.000807	0.00161	CcSEcCtD
Bexarotene—Pruritus—Fluorouracil—head and neck cancer	0.000806	0.00161	CcSEcCtD
Bexarotene—Thrombocytopenia—Docetaxel—head and neck cancer	0.000805	0.00161	CcSEcCtD
Bexarotene—Tachycardia—Docetaxel—head and neck cancer	0.000803	0.0016	CcSEcCtD
Bexarotene—Skin disorder—Docetaxel—head and neck cancer	0.000799	0.0016	CcSEcCtD
Bexarotene—RXRB—Gene Expression—YAP1—head and neck cancer	0.00079	0.00176	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NOTCH1—head and neck cancer	0.000786	0.00175	CbGpPWpGaD
Bexarotene—Anorexia—Docetaxel—head and neck cancer	0.000784	0.00157	CcSEcCtD
Bexarotene—Diarrhoea—Fluorouracil—head and neck cancer	0.00078	0.00156	CcSEcCtD
Bexarotene—Dizziness—Fluorouracil—head and neck cancer	0.000754	0.0015	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000749	0.0015	CcSEcCtD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000745	0.00166	CbGpPWpGaD
Bexarotene—Insomnia—Docetaxel—head and neck cancer	0.000744	0.00149	CcSEcCtD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00074	0.00165	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NOTCH1—head and neck cancer	0.000739	0.00165	CbGpPWpGaD
Bexarotene—Paraesthesia—Docetaxel—head and neck cancer	0.000739	0.00147	CcSEcCtD
Bexarotene—Dyspnoea—Docetaxel—head and neck cancer	0.000733	0.00146	CcSEcCtD
Bexarotene—Somnolence—Docetaxel—head and neck cancer	0.000731	0.00146	CcSEcCtD
Bexarotene—Vomiting—Fluorouracil—head and neck cancer	0.000725	0.00145	CcSEcCtD
Bexarotene—Dyspepsia—Docetaxel—head and neck cancer	0.000724	0.00145	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000719	0.0016	CbGpPWpGaD
Bexarotene—Rash—Fluorouracil—head and neck cancer	0.000718	0.00143	CcSEcCtD
Bexarotene—Dermatitis—Fluorouracil—head and neck cancer	0.000718	0.00143	CcSEcCtD
Bexarotene—Decreased appetite—Docetaxel—head and neck cancer	0.000715	0.00143	CcSEcCtD
Bexarotene—Headache—Fluorouracil—head and neck cancer	0.000714	0.00143	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00071	0.00142	CcSEcCtD
Bexarotene—Fatigue—Docetaxel—head and neck cancer	0.000709	0.00142	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000706	0.00158	CbGpPWpGaD
Bexarotene—Pain—Docetaxel—head and neck cancer	0.000703	0.0014	CcSEcCtD
Bexarotene—Constipation—Docetaxel—head and neck cancer	0.000703	0.0014	CcSEcCtD
Bexarotene—Feeling abnormal—Docetaxel—head and neck cancer	0.000678	0.00135	CcSEcCtD
Bexarotene—Nausea—Fluorouracil—head and neck cancer	0.000677	0.00135	CcSEcCtD
Bexarotene—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000673	0.00134	CcSEcCtD
Bexarotene—Abdominal pain—Docetaxel—head and neck cancer	0.00065	0.0013	CcSEcCtD
Bexarotene—Body temperature increased—Docetaxel—head and neck cancer	0.00065	0.0013	CcSEcCtD
Bexarotene—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000628	0.0014	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—STAT3—head and neck cancer	0.000611	0.00136	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.000606	0.00135	CbGpPWpGaD
Bexarotene—Hypersensitivity—Docetaxel—head and neck cancer	0.000606	0.00121	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000602	0.00134	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000594	0.00133	CbGpPWpGaD
Bexarotene—Asthenia—Docetaxel—head and neck cancer	0.00059	0.00118	CcSEcCtD
Bexarotene—Pruritus—Docetaxel—head and neck cancer	0.000582	0.00116	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000576	0.00128	CbGpPWpGaD
Bexarotene—Diarrhoea—Docetaxel—head and neck cancer	0.000563	0.00112	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000554	0.00124	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000546	0.00122	CbGpPWpGaD
Bexarotene—Dizziness—Docetaxel—head and neck cancer	0.000544	0.00109	CcSEcCtD
Bexarotene—Vomiting—Docetaxel—head and neck cancer	0.000523	0.00104	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.00052	0.00116	CbGpPWpGaD
Bexarotene—Rash—Docetaxel—head and neck cancer	0.000519	0.00104	CcSEcCtD
Bexarotene—Dermatitis—Docetaxel—head and neck cancer	0.000518	0.00103	CcSEcCtD
Bexarotene—Headache—Docetaxel—head and neck cancer	0.000515	0.00103	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000502	0.00112	CbGpPWpGaD
Bexarotene—Nausea—Docetaxel—head and neck cancer	0.000489	0.000976	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000488	0.00109	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	0.000454	0.00101	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—RARB—head and neck cancer	0.000452	0.00101	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	0.000429	0.000957	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000415	0.000925	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—YAP1—head and neck cancer	0.000412	0.000918	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000409	0.000912	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000408	0.000911	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	0.000408	0.000911	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	0.000408	0.000911	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000404	0.000902	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000393	0.000877	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000388	0.000865	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH1—head and neck cancer	0.000385	0.00086	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NAT2—head and neck cancer	0.000385	0.000858	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH1—head and neck cancer	0.000379	0.000845	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NOTCH1—head and neck cancer	0.000363	0.000809	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH1—head and neck cancer	0.000356	0.000794	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	0.000354	0.00079	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—UROD—head and neck cancer	0.000346	0.000771	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	0.000343	0.000765	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—DPYD—head and neck cancer	0.000337	0.000752	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—YAP1—head and neck cancer	0.00032	0.000714	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	0.000289	0.000646	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000273	0.00061	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.00027	0.000602	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000268	0.000599	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000259	0.000578	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000256	0.00057	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.00024	0.000536	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—UROD—head and neck cancer	0.000228	0.000509	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—VEGFA—head and neck cancer	0.000212	0.000473	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—STAT3—head and neck cancer	0.00021	0.000469	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.00021	0.000468	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MAPK3—head and neck cancer	0.000209	0.000467	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MAPK3—head and neck cancer	0.000201	0.000448	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MAPK3—head and neck cancer	0.000197	0.000439	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TYMS—head and neck cancer	0.000192	0.000429	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MAPK1—head and neck cancer	0.000191	0.000426	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—head and neck cancer	0.000191	0.000426	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTM1—head and neck cancer	0.00019	0.000424	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NOTCH1—head and neck cancer	0.000185	0.000414	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GPX1—head and neck cancer	0.000182	0.000406	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP1A1—head and neck cancer	0.00018	0.000402	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—head and neck cancer	0.000153	0.000342	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000152	0.00034	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000151	0.000337	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000148	0.00033	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NAT2—head and neck cancer	0.000144	0.00032	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—AKT1—head and neck cancer	0.000141	0.000315	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—AKT1—head and neck cancer	0.000135	0.000302	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—AKT1—head and neck cancer	0.000133	0.000296	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—DPYD—head and neck cancer	0.000126	0.000281	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—YAP1—head and neck cancer	0.000119	0.000267	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS2—head and neck cancer	0.000107	0.000239	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MAPK3—head and neck cancer	0.000103	0.000229	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NAT2—head and neck cancer	9.47e-05	0.000211	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTEN—head and neck cancer	9.34e-05	0.000208	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	8.98e-05	0.0002	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—DPYD—head and neck cancer	8.3e-05	0.000185	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—YAP1—head and neck cancer	7.88e-05	0.000176	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.83e-05	0.000175	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TYMS—head and neck cancer	7.17e-05	0.00016	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTM1—head and neck cancer	7.09e-05	0.000158	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—AKT1—head and neck cancer	6.92e-05	0.000154	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GPX1—head and neck cancer	6.79e-05	0.000152	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP1A1—head and neck cancer	6.72e-05	0.00015	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CA—head and neck cancer	6.59e-05	0.000147	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.52e-05	0.000123	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKT1—head and neck cancer	5.38e-05	0.00012	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TYMS—head and neck cancer	4.73e-05	0.000106	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTM1—head and neck cancer	4.68e-05	0.000104	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GPX1—head and neck cancer	4.48e-05	9.99e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP1A1—head and neck cancer	4.43e-05	9.89e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS2—head and neck cancer	4e-05	8.92e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTEN—head and neck cancer	3.49e-05	7.78e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.64e-05	5.88e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.46e-05	5.49e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTEN—head and neck cancer	2.3e-05	5.13e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKT1—head and neck cancer	2.01e-05	4.48e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.62e-05	3.62e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKT1—head and neck cancer	1.33e-05	2.96e-05	CbGpPWpGaD
